Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | THEO-260 |
Synonyms | |
Therapy Description |
THEO-260 is an oncolytic adenovirus that may induce lysis of tumor cells and cancer-associated fibroblasts, potentially resulting in decreased tumor growth (J Clin Oncol, 41, no. 16_suppl (2023) e14573, Ann Oncol (2023) 34 (suppl_2): S1166). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
THEO-260 | THEO 260|THEO260 | THEO-260 is an oncolytic adenovirus that may induce lysis of tumor cells and cancer-associated fibroblasts, potentially resulting in decreased tumor growth (J Clin Oncol, 41, no. 16_suppl (2023) e14573, Ann Oncol (2023) 34 (suppl_2): S1166). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT06618235 | Phase Ib/II | THEO-260 | Trial of THEO-260 in Ovarian Cancer Patients (OCTOPOD) | Recruiting | GBR | 0 |